Who
Elliott M. Levy
Director
Company insider
Files Form 4 as: Director, NuCana; Director, Editas Medicine; Director, Omega Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 8 Jun 2022
- Last trade
- 19 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Jun 2026filed 24 Jun 2026 | NCNA NuCanaoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,811,896 at $0.00 | filing |
| 19 Jun 2026filed 24 Jun 2026 | NCNA NuCanaoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,811,896 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —18,118 at $0.00 | filing |
| 11 Apr 2023filed 13 Apr 2023 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —18,118 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.